Search details
1.
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
Ann Hematol
; 2024 Apr 13.
Article
in English
| MEDLINE | ID: mdl-38609726
2.
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
Chemotherapy
; 63(4): 220-224, 2018.
Article
in English
| MEDLINE | ID: mdl-30372691
3.
Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation.
Transfusion
; 56(5): 1096-1100, 2016 May.
Article
in English
| MEDLINE | ID: mdl-27021516
4.
Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide.
Biol Blood Marrow Transplant
; 20(5): 724-9, 2014 May.
Article
in English
| MEDLINE | ID: mdl-24530426
5.
A case of high-risk AML in a patient with advanced systemic mastocytosis.
Clin Case Rep
; 11(7): e7134, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-37469366
6.
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience.
Front Immunol
; 14: 1195734, 2023.
Article
in English
| MEDLINE | ID: mdl-37809082
7.
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data.
Healthcare (Basel)
; 11(10)2023 May 18.
Article
in English
| MEDLINE | ID: mdl-37239765
8.
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.
Blood Adv
; 7(16): 4448-4461, 2023 08 22.
Article
in English
| MEDLINE | ID: mdl-37276451
9.
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases.
Hematol Rep
; 14(2): 67-72, 2022 Mar 24.
Article
in English
| MEDLINE | ID: mdl-35466175
10.
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field.
Cancers (Basel)
; 14(9)2022 Apr 27.
Article
in English
| MEDLINE | ID: mdl-35565314
11.
Therapeutic innovation for multi-resistant candidemics: Synergy of isavuconazole and caspofungin association.
Hematol Rep
; 13(4): 9329, 2021 Nov 26.
Article
in English
| MEDLINE | ID: mdl-35070221
12.
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database.
Front Pharmacol
; 12: 748766, 2021.
Article
in English
| MEDLINE | ID: mdl-34899303
13.
Intermediate dose etoposide plus G-CSF 16 g/kg is more effective than cyclophosphamide 4 g/m(2) plus G-CSF 10 g/kg in PBSC mobilization of lymphoma patients.
Leuk Lymphoma
; 48(10): 1950-60, 2007 Oct.
Article
in English
| MEDLINE | ID: mdl-17917963
14.
Pegylated Asparaginase-Induced Liver Injury: A Case-Based Review and Data From Pharmacovigilance.
J Clin Pharmacol
; 62(9): 1142-1150, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35342960
15.
CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.
Leuk Res
; 41: 36-42, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26754556
16.
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization.
Leuk Res
; 35(7): 899-903, 2011 Jul.
Article
in English
| MEDLINE | ID: mdl-21134693
Results
1 -
16
de 16
1
Next >
>>